Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT04084366
• Recruitment Status: Recruiting
• First Posted: September 10, 2019
• Last Update Posted: July 7, 2022
• Sponsor: OBI Pharma, Inc
• Information provided by (Responsible Party): OBI Pharma, Inc

Study Description

Brief Summary:

The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.

Condition or disease	Intervention/treatment	Phase
Locally Advanced Solid Tumor	Drug: OBI-999	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 185 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
• Actual Study Start Date: December 10, 2019
• Estimated Primary Completion Date: November 9, 2023
• Estimated Study Completion Date: December 9, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: OBI-999 Escalation phase; Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).	Drug: OBI-999; For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Experimental: OBI-999 Expansion Phase; Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.	Drug: OBI-999; For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.

Outcome Measures

Primary Outcome Measures :

1. Measurement of dose-limiting toxicities (DLTs) [ Time Frame: First 21 days of each dose escalation cohort ]
   Percentage of patients with dose-limiting toxicities (DLTs) observed
2. Identification of a maximum tolerated dose and recommended phase 2 dose for OBI-999 [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with adverse events/serious adverse events and laboratory abnormalities as graded by NCI CTCAE version 5.0

Secondary Outcome Measures :

1. Measurement of preliminary clinical activity profile (objective response rate [ORR]) of OBI-999 in patients. [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with ORR per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
2. Measurement of preliminary clinical activity profile (clinical benefit rate [CBR]) of OBI-999 in patients. [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with CBR per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
3. Measurement of preliminary clinical activity profile (duration of response (DOR)]) of OBI-999 in patients. [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
4. Measurement of preliminary clinical activity profile (progression-free survival [PFS]) of OBI-999 in patients. [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with PFS per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
5. Measurement of OBI-999 immunogenicity (anti-drug antibodies ([ADAs]) in patients [ Time Frame: Week 1 to Week 106 ]
   Percentage of patients with anti-OBI-999 antibodies in blood.
6. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - Cmax [ Time Frame: Week 1 to Week 106 ]
   PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2
7. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - total exposure (area under curve, [AUC]) [ Time Frame: Week 1 to Week 106 ]
   PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2
8. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - elimination half-life (t1/2) [ Time Frame: Week 1 to Week 106 ]
   PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2
9. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - clearance (C1) [ Time Frame: Week 1 to Week 106 ]
   PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2
10. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - time to reach maximum concentration (Tmax) [ Time Frame: Week 1 to Week 106 ]
    PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2
11. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) - volume of distribution (Vd) [ Time Frame: Week 1 to Week 106 ]
    PK parameters will be calculated using a non-compartmental method from the PK samples collected during Cycles 1 and 2

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female patients, 18 years of age or older at the time of consent.
2. Provide written informed consent prior to performing any study related procedure.
3. Histologically or cytologically confirmed patients with advanced solid tumors.
4. Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the informed consent must state the effective therapies the patient is declining.
5. Measurable disease (i.e., at least one measurable lesion per RECIST 1.1)
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

7. Adequate organ function defined as:

   a. Hepatic:

   i. Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases

   ii. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases

   iii.Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis)

   b. Renal:

   i. Creatinine clearance >50 mL/minute using Cockcroft Gault equation

   c. Hematologic:

   i. Absolute neutrophil count ≥1,500/µL

   ii. Platelets ≥100,000/µL

   iii. Hemoglobin ≥8 g/dL

8. Patient is willing and able to comply with all protocol required assessments, visits, and procedures, including a pretreatment tumor biopsy. Archival tumor biopsies are acceptable at baseline.

9. Females of childbearing potential must have negative serum pregnancy test prior to starting study therapy, and agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug.

   Patient not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.

   Male patients must agree to use an adequate method of contraception during the study treatment period and for at least 120 days following the last dose of study drug.

10. Cannot be breast feeding.
11. Patients with human immunodeficiency virus (HIV) infection are eligible if CD4+ T cell counts ≥ 350 cells/uL; patients on antiretroviral therapy (ART) should be on an established dose for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.
12. Patients with serological evidence of chronic hepatitis B virus (HBV) infection are eligible if they have an HBV viral load below the limit of quantification with or without concurrent viral suppressive therapy.
13. Patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and have a viral load below the limit of quantification.

14. Patients in Part B (Cohort-Expansion) must have documented Globo H H score of at least 100 from a qualified laboratory IHC assay in one of the sponsor-selected tumor types to be enrolled in the respective cohort:

    • Cohort 1: Pancreatic cancer
    • Cohort 2: Esophageal cancer
    • Cohort 3: Gastric cancer
    • Cohort 4: Colorectal cancer
    • Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1 through 4).

Exclusion Criteria:

1. Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of OBI 999.
2. Has undergone a major surgical procedure (as defined by the Investigator) or significant traumatic injury within 28 days prior to the first dose of OBI 999.
3. Sensory or motor neuropathy of Grade 2 or greater.
4. Patients with a history of solid organ transplant.
5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.
6. Receipt of any prior therapy targeting Globo H.
7. Known hypersensitivity to OBI 999 or its excipients.
8. Has known untreated central nervous system metastases. Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period.
9. Has significant clinical cardiac abnormality (e.g., clinical heart failure or unstable angina)
10. Any medical co morbidity that is life threatening or, in the opinion of the Investigator, renders the patient unsuitable for participation in a clinical trial due to possible noncompliance, would place the patient at an unacceptable risk and/or potential to affect interpretation of results of the study.
11. Is receiving any concurrent prohibited medication

Contacts and Locations

Contacts

Contact: OBI Pharma CT.gov Assistant; 1-619-537-7821; ClinicalTrials.gov-queries@obipharmausa.com

Locations

United States, California

Scripps MD Anderson Cancer Center; Recruiting

La Jolla, California, United States, 92037

United States, New York

Memorial Sloan Kettering Cancer Center; Recruiting

New York, New York, United States, 10065

United States, Tennessee

West Cancer Center; Recruiting

Germantown, Tennessee, United States, 38138

United States, Texas

University of Texas MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Sponsors and Collaborators

OBI Pharma, Inc

Investigators

• Principal Investigator: Apostolia Tsimberidou, MD, PhD; M.D. Anderson Cancer Center

More Information

• Responsible Party: OBI Pharma, Inc
• ClinicalTrials.gov Identifier: NCT04084366
• Other Study ID Numbers: OBI-999-001
• First Posted: September 10, 2019
• Last Update Posted: July 7, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by OBI Pharma, Inc:

antibody drug conjugate (ADC)

Additional relevant MeSH terms:

Neoplasms